Research & Development
NICE recommends genedrive's CYP2C19-ID kit for UK point-of-care genotype testing
3 April 2024 -

Point of care pharmacogenetic testing company genedrive plc (AIM:GDR) announced on Wednesday that the UK's National Institute for Health and Care Excellence (NICE) has recommended the Genedrive CYP2C19-ID test as the preferred platform for point-of-care genotype testing before clopidogrel administration in managing Ischemic Stroke (IS) and Transient Ischaemic Attack (TIA) patients.

Clopidogrel is an antiplatelet drug used after IS or TIA to reduce the risk of blood clots that can cause further strokes. Its effectiveness varies due to genetic variations in the CYP2C19 gene, impacting enzyme function.

With a non-invasive cheek swab sample, the Genedrive CYP2C19-ID test swiftly identifies six key genetic variants of the CYP2C19 gene, crucial for metabolism function. The Genedrive System provides clinicians with automatic interpretation, allowing prompt treatment optimisation.

NICE initially proposed CYP2C19 genetic testing prior to antiplatelet treatment in May 2023. Following a public consultation, final recommendations are anticipated from NICE in July 2024.